In studying the effectiveness of infliximab, adalimumab and certolizumab for inducing remission in Crohn's disease, the article by Kawalec et al. [1] included a comprehensive series of pair-wise meta-analyses that compared individual biologic agents versus placebo (direct comparisons), but did not study the indirect comparisons of biologics with one another, an issue that can be managed by application of network meta-analysis. To better address the clinical relevance of differences between these biologics, equivalence testing is another point that can be worthwhile to investigate based on these data. In fact, differentiating between no proof of difference (an "inconclusive result" [2] ) and proof of no difference (equivalence, a "conclusive" result [2] ) is increasingly recognised to be a crucial step for a correct interpretation of both meta-analyses and clinical trials [3, 4] .
RD = 12.1% (95% CI: -5.0% to 29.2%) RD = 9.3% (95% CI: 5.5% to 13.2%) RD = -4.5% (95% CI: -11.2% to 2.2%) RD Figure 1 . Head-to-head indirect comparisons of three biological treatments for inducing remission in ulcerative colitis: network meta-analysis (A) and equivalence testing based on a forest plot (B). The outcome measure for each of these indirect pair-wise comparisons was the achievement of remission (expressed as a percentage). The meta-analytic values of RD (with 95% CIs) were extracted from reference [6] . A -This type of graph (simplified figure according to Fadda et al. [7] ) summarises the results but does not allow us to differentiate between "no proof of difference" and "proof of no difference". Statistical calculations according to Bucher's method [7] . Symbols: +, more effective at statistical level of p < 0.05; -, less effective at statistical level of p < 0.05; = , no difference; t, indicates which treatment is favoured by a trend in cases of no difference. B -The equivalence test is based on the area comprised between the two vertical dashed lines, that reflect the pre-determined equivalence margins (from -15% to +15%). Each horizontal bar indicates the two-sided 95% CI for the RD (solid square). The criterion for demonstrating equivalence is when both extremes of the 95% CI remain within the two vertical dashed lines. Comparisons: [1] infliximab vs. certolizumab (in green): RD = 16.6% (95% CI: 0.15% to 33.0%); [2] infliximab vs adalimumab (in brown): RD = 12.1% (95% CI: -5.0% to 20.2%); [3] certolizumab vs adalimumab (in blue): RD = -4.5% (95% CI: -10.9% to 1.9%)
RD -risk difference, CI -confidence interval.
In summary, our results (Figure 1 ) indicate that these two subcutaneous agents are therapeutically equivalent, at least for this indication. There are, of course, some limitations in the present study. One controversial point concerns these mixed analytical approaches based on meta-analysis plus pre-specified margins, because margins are known to possess a certain component of arbitrariness [8] . Furthermore, there can be some controversy as to whether the end-point of remission achievement can fully account for all the main effects of these agents, because other outcomes can be relevant as well [9, 10] .
In conclusion, this network meta-analysis showed the equivalence between the two subcutaneous biologics. Despite this evidence, our findings confirm that there is still an unmet need for large, well-designed, controlled trials providing reliable comparisons between anti-TNF therapies in the treatment of Crohn's disease.
